Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
09:45am, Thursday, 18'th Sep 2025
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
06:14pm, Wednesday, 17'th Sep 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week exten
Lilly's GLP-1 Pill Outperforms Older Novo Drug
10:39am, Wednesday, 17'th Sep 2025
Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial
Lilly's GLP-1 pill seen as superior in head-to-head trial with Novo's oral semaglutide
10:28am, Wednesday, 17'th Sep 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details about Eli Lilly's new drug trial.
GLP-1 drugs could save millions of lives — and spark a pension crisis
10:05am, Wednesday, 17'th Sep 2025
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study
09:03am, Wednesday, 17'th Sep 2025
Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with diabetes than oral semaglutide, the active ingredient in Danish rival Novo
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
09:00am, Wednesday, 17'th Sep 2025
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%)
Swiss Re says GLP-1 drugs could reduce US mortality by up to 6.4%
05:27am, Wednesday, 17'th Sep 2025
Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up to 6.4% in the United States by 2045.
- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. - ASC30 tablet's higher eff
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study Orforglipron demonstrated significant improvements acro
I Own The Gas Pump With Up To 10% Yields
10:30am, Saturday, 13'th Sep 2025
Pump fuel – get paid by these generous opportunities. Fuel distribution is essential for our economy, but often overlooked. All three opportunities covered issue a K-1 at tax time.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
06:30am, Saturday, 13'th Sep 2025
The oral GLP-1 segment is entering a pivotal stage, with major growth anticipated from 2026 onward. Patient preference for oral pills over injectables is strong, making ease of use a key driver for fu
Novo Nordisk: GLP-1's Concerns Are Overblown
04:41am, Saturday, 13'th Sep 2025
Novo continues to face U.S. market share pressure from Eli Lilly's Tirzepatide based GLP-1 and off-label semaglutide, but retains strong international GLP-1 dominance with 71% market share outside the
GLP-1 obesity pills face off in head-to-head trial
12:39pm, Friday, 12'th Sep 2025
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
